Skip to main content

A first in category prescription regimen for ADHD combining stimulants with intelligent dosing and digital capabilities


The goal of this project is to develop a therapy that allows for more effective management of attention-deficit hyperactivity disorder (ADHD). ADHD is a common, childhood onset, neurobehavioural disorder characterised by a combination of inattention, hyperactivity and impulsivity impairing multiple areas of life. Stimulants are the most widely used ADHD medications and are proven effective on ADHD symptoms, but classified as controlled substances they are associated with concerns about side effects and potential for abuse. In addition, they require careful dose titration at initiation and throughout the patients’ life.

OnDosis aims to address these challenges by developing a novel “combination product”, prescribed as an ADHD treatment regime, that combines a technological platform with stimulant active compounds. This integrated solution will simplify dose titration, enable ease of swallowing, offer adherence support and self-monitoring checks. Importantly, OnDosis’ solution is a personalised device with the potential to reduce risk for medication abuse through tamper resistance and tamper evident features.

The ultimate success of the project will depend on generation of clinical data which will support partnering and out-licensing. OnDosis plans to apply for SMEi Phase 2 grant to take the product through required clinical studies, and then go to market through a licensing agreement with a strong commercial partner. OnDosis has a strong network established with potential pharma partners and investors, and has already gained support from investors that offer strategic support to the company.

The burden of ADHD is increasing and the unmet need is growing. This encourages OnDosis in the endeavour of a needs-driven research to address this widespread challenge. Market research with several stakeholders in healthcare have convinced OnDosis of the potential to bring significant impact to patients with ADHD through this novel technology.

Field of science

  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /social sciences/economics and business/business and management/commerce

Call for proposal

See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1


Astrazeneca Bioventurehub, Peppared
431 50 Molndal
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000